Oncodesign Precision Medicine Opm SA

Oncodesign Precision Medicine Opm SA has a fully diluted share count of 18,134,475 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. The company's liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents, suggesting potential financial instability or lack of transparency. The company's profitability metrics are not available in the valuation snapshot, but its last actual revenue was reported at 260,000 EUR, significantly below the mean revenue estimate of 101.8 million EUR. This suggests a substantial gap between current performance and analyst expectations, potentially indicating underperformance relative to industry_config preferred metrics for healthcare diagnostics firms. Geographic and segment exposure data are not disclosed in the available source documents, making it impossible to assess revenue concentration or geographic diversification. This lack of transparency could pose a risk to investors seeking to understand the company's market positioning and operational resilience. The company's growth trajectory appears highly uncertain, with a last actual revenue of 260,000 EUR versus a mean revenue estimate of 101.8 million EUR, representing a 99.7% growth expectation. However, without historical revenue data or a clear path to scaling, this projection remains speculative. The risk assessment indicates low dilution risk but highlights the inability to assess liquidity risk due to missing financial data. This suggests potential operational or financial instability, which could affect the company's ability to meet short-term obligations or fund growth initiatives. Recent events include the publication of analyst estimates showing a mean EPS estimate of 4.03 EUR and a mean EBIT estimate of 88.6 million EUR, despite the company's last actual revenue being only 260,000 EUR. These estimates suggest a significant disconnect between current performance and analyst expectations, potentially indicating over-optimism or a lack of reliable financial reporting.